financetom
Business
financetom
/
Business
/
Travel & Leisure Insider Sold Shares Worth $1,478,293, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Travel & Leisure Insider Sold Shares Worth $1,478,293, According to a Recent SEC Filing
Feb 25, 2025 1:46 PM

04:23 PM EST, 02/25/2025 (MT Newswires) -- James J Savina, General Counsel and Corporate Secretary, on February 24, 2025, sold 26,442 shares in Travel & Leisure (TNL) for $1,478,293. Following the Form 4 filing with the SEC, Savina has control over a total of 63,049 common shares of the company, with 63,049 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1361658/000136165825000030/xslF345X05/wk-form4_1740518038.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Beam Therapeutics Says Conditioning Platform Shows Potential in Sickle Cell Disease Treatment
Beam Therapeutics Says Conditioning Platform Shows Potential in Sickle Cell Disease Treatment
Dec 9, 2024
04:43 AM EST, 12/09/2024 (MT Newswires) -- Beam Therapeutics ( BEAM ) said Sunday new data for its engineered stem cell antibody evasion conditioning platform showed that conditioning and in vivo selection with an anti-CD117 antibody allowed engraftment of base-edited hematopoietic stem cells in a non-human primate model. Engraftment is the process under which transplanted stem cells enter the bloodstream,...
PRESS DIGEST- Wall Street Journal - Dec 9
PRESS DIGEST- Wall Street Journal - Dec 9
Dec 9, 2024
Dec 9 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - Omnicom Group ( OMC ) is in advanced talks to acquire Interpublic Group in an all-stock deal, which is likely to value Interpublic at between $13 billion and $14 billion. -...
Agios Pharmaceuticals Meets Phase 3 Primary, Secondary Goals
Agios Pharmaceuticals Meets Phase 3 Primary, Secondary Goals
Dec 9, 2024
04:38 AM EST, 12/09/2024 (MT Newswires) -- Agios Pharmaceuticals ( AGIO ) said Sunday the phase 3 study of its experimental drug mitapivat to treat adults with transfusion-dependent alpha- or beta-thalassemia, a rare blood disease, met primary and secondary goals. In the study, mitapivat demonstrated a statistically significant reduction in transfusion burden compared with placebo, the company said. The company...
Merck's Study Shows Complete Response Rate of 100% for Zilovertamab Vedotin With R-CHP in Cancer Patients
Merck's Study Shows Complete Response Rate of 100% for Zilovertamab Vedotin With R-CHP in Cancer Patients
Dec 9, 2024
04:54 AM EST, 12/09/2024 (MT Newswires) -- Merck & Co. ( MRK ) said Sunday that its phase 2 waveLINE-007 trial evaluating zilovertamab vedotin, its investigational antibody-drug conjugate in combination with R-CHP for the treatment of patients with previously untreated diffuse large B-cell lymphoma, achieved a 100% complete response rate. Patients were treated with the drug at 1.75 mg/kg, which...
Copyright 2023-2026 - www.financetom.com All Rights Reserved